Exicure (XCUR) Total Debt (2016 - 2024)

Exicure's (XCUR) quarterly Total Debt came in at $1.0 million in Q2 2024, down 85.45% on a QoQ basis from $6.9 million in Q4 2021.

Exicure (XCUR) Total Debt (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 7 years of Total Debt data on file, last reported at $1.0 million in Q2 2024.

Quarterly Total Debt changed N/A year-over-year to $1.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $1.0 million (changed N/A YoY) and the FY2021 annual result came in at $6.9 million, down 58.57% from the prior year.
Total Debt retreated to $1.0 million in Q2 2024, from $6.9 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $16.8 million in Q3 2021 to a low of $1.0 million in Q2 2024.
A 3-year average of $13.0 million and a median of $16.6 million in 2020 frame the typical range for Total Debt.
Annual changes were most pronounced in 2020 — Total Debt soared 234.12% — and 2021, when it tumbled 58.57%.
Tracing XCUR's Total Debt over 3 years: stood at $16.6 million in 2020, then plunged by 58.57% to $6.9 million in 2021, then slumped by 85.45% to $1.0 million in 2024.
The last three Total Debt figures came in at $1.0 million (Q2 2024), $6.9 million (Q4 2021), and $16.8 million (Q3 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Exicure	8.41 Mn	8.41 Mn	-	1.21 Mn

Download Data